share_log

Reported Earlier, Adaptimmune's TECELRA Gains U.S. FDA Accelerated Approval As First Engineered Cell Therapy For Solid Tumors

Reported Earlier, Adaptimmune's TECELRA Gains U.S. FDA Accelerated Approval As First Engineered Cell Therapy For Solid Tumors

適應免疫技術的TECELRA作爲首個用於實體瘤工程細胞療法獲得美國FDA的加速批准
Benzinga ·  08/02 03:17
  • Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy
  • TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade
  • 愛文思控股已獲批用於成人HLA 型號特定的MAGE-A4+滑膜肉瘤經過化療的治療。
  • TECELRA是滑膜肉瘤患者十年來的第一個新治療選擇。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論